Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [21] CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S205 - S209
  • [22] Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors
    Hayama, Shouko
    Nakamura, Rikiya
    Miyaki, Toshiko
    Itami, Makiko
    Yamamoto, Naohito
    BREAST CARE, 2022, 17 (01) : 16 - 23
  • [23] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [24] CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update
    O'Sullivan, Ciara C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1657 - 1667
  • [25] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [26] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [27] CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
    Laderian, Bahar
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 395 - 403
  • [28] Targeting CDK4/6 pathways and beyond in breast cancer
    Ribnikar, Domen
    Volovat, Simona Ruxandra
    Cardoso, Fatima
    BREAST, 2019, 43 : 8 - 17
  • [29] Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer
    Duso, Bruno Achutti
    Trapani, Dario
    Viale, Giulia
    Criscitiello, Carmen
    D'Amico, Paolo
    Belli, Carmen
    Mazzarella, Luca
    Locatelli, Marzia
    Minchella, Ida
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (03) : 299 - 305
  • [30] Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
    Gao, Hong-Fei
    Lin, Ying-Yi
    Zhu, Teng
    Ji, Fei
    Zhang, Liu-Lu
    Yang, Ci-Qiu
    Yang, Mei
    Li, Jie-Qing
    Cheng, Min-Yi
    Wang, Kun
    BREAST, 2021, 59 : 165 - 175
12345